crovalimab-akkz (Piasky)
crovalimab-akkz is an FDA-licensed reference biologic from Genentech, Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2024
Reference approved
Reference product
Piasky crovalimab-akkz
Genentech, Inc.
- Approved
- Jun 20, 2024
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for crovalimab-akkz, in chronological order.
Reference approval
Approval date of the reference crovalimab-akkz product.
2 yr ago
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
in 5 yr 2 mo
Frequently asked questions
Are there biosimilars approved for crovalimab-akkz (Piasky)?
No 351(k) biosimilars or interchangeable biosimilars referencing crovalimab-akkz are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.